RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew's RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category. This award recognizes its intuitive pairing of NPWT in a patient-friendly design. The system, launched in 2024, is designed for treating chronic wounds, which affect an estimated 8.2 million people in the US with an annual financial burden of $33 billion.
The RENASYS EDGE NPWT System is lightweight, compact, and quiet, allowing patients to easily carry or wear it without drawing attention to their condition. This design consideration is crucial, as 68% of patients with chronic wounds often become self-conscious and isolated. Smith+Nephew's focus on patient-centric design is further evidenced by their PICO◊ 14 NPWT System, which also won a Red Dot Award for Design Concept in 2021 for its portable and discreet design.
Il sistema RENASYS EDGE per la terapia delle ferite a pressione negativa (NPWT) di Smith+Nephew ha vinto il Red Dot Award per il Concept di Design 2024 nella categoria Dispositivi Medici e Tecnologia. Questo premio riconosce la sua abbinamento intuitivo della NPWT a un design amichevole per i pazienti. Il sistema, lanciato nel 2024, è progettato per trattare ferite croniche, che colpiscono circa 8,2 milioni di persone negli Stati Uniti, con un onere finanziario annuale di 33 miliardi di dollari.
Il sistema RENASYS EDGE NPWT è leggero, compatto e silenzioso, consentendo ai pazienti di portarlo o indossarlo facilmente senza attirare l'attenzione sulla loro condizione. Questa considerazione di design è cruciale, poiché il 68% dei pazienti con ferite croniche diventa spesso insicuro e isolato. L'attenzione di Smith+Nephew per un design incentrato sul paziente è ulteriormente dimostrata dal loro PICO◊ 14 NPWT System, che ha vinto anch'esso un Red Dot Award per il Concept di Design nel 2021 per il suo design portatile e discreto.
El sistema RENASYS EDGE de terapia de presión negativa de heridas (NPWT) de Smith+Nephew ha ganado el Red Dot Award por Concepto de Diseño 2024 en la categoría de Dispositivos Médicos y Tecnología. Este premio reconoce su emparejamiento intuitivo de NPWT en un diseño amigable para el paciente. El sistema, lanzado en 2024, está diseñado para tratar heridas crónicas, que afectan a aproximadamente 8.2 millones de personas en los EE. UU. con una carga financiera anual de 33 mil millones de dólares.
El sistema RENASYS EDGE NPWT es ligero, compacto y silencioso, permitiendo que los pacientes lo lleven o usen fácilmente sin llamar la atención sobre su condición. Esta consideración de diseño es crucial, ya que el 68% de los pacientes con heridas crónicas a menudo se vuelven inseguros y se aíslan. El enfoque de Smith+Nephew en un diseño centrado en el paciente se evidencia aún más con su PICO◊ 14 NPWT System, que también ganó un Red Dot Award por Concepto de Diseño en 2021 por su designación portátil y discreta.
Smith+Nephew의 RENASYS EDGE 부정압 상처 치료(NPWT) 시스템이 2024년 레드닷 디자인 콘셉트 어워드에서 의료기기 및 기술 부문에서 수상했습니다. 이 상은 환자 친화적인 디자인에 NPWT를 직관적으로 결합한 점을 인정받은 것입니다. 2024년에 출시된 이 시스템은 미국에서 약 820만 명에게 영향을 미치는 만성 상처 치료를 위해 설계되었습니다. 연간 재정 부담은 330억 달러에 달합니다.
RENESYS EDGE NPWT 시스템은 가볍고, 컴팩트하며, 조용합니다, 환자들이 자신의 상태에 주목받지 않고 쉽게 휴대하거나 착용할 수 있도록 해줍니다. 이 디자인 고려는 매우 중요합니다. 만성 상처를 가진 환자의 68%가 종종 불안해하고 고립감을 느끼기 때문입니다. Smith+Nephew의 환자 중심 디자인에 대한 집중은 또한 2021년에 휴대 가능하고 은밀한 디자인으로 레드닷 디자인 상을 수상한 PICO◊ 14 NPWT System에서 더욱 입증됩니다.
Le système RENASYS EDGE pour la thérapie des plaies par pression négative (NPWT) de Smith+Nephew a remporté le Red Dot Award pour le concept de design 2024 dans la catégorie Dispositifs médicaux et technologies. Ce prix reconnaît son association intuitive de la NPWT dans un design convivial pour les patients. Le système, lancé en 2024, est conçu pour traiter les plaies chroniques, qui touchent environ 8,2 millions de personnes aux États-Unis, avec un fardeau financier annuel de 33 milliards de dollars.
Le système RENASYS EDGE NPWT est léger, compact et silencieux, permettant aux patients de le porter ou de le porter facilement sans attirer l'attention sur leur condition. Cette considération de design est cruciale, car 68 % des patients souffrant de plaies chroniques deviennent souvent sensibles et isolés. L'accent mis par Smith+Nephew sur un design centré sur le patient est encore renforcé par leur PICO◊ 14 NPWT System, qui a également remporté un Red Dot Award pour le concept de design en 2021 grâce à son design portable et discret.
Das RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System von Smith+Nephew hat den Red Dot Award für Designkonzept 2024 in der Kategorie Medizintechnik und Technologie gewonnen. Diese Auszeichnung würdigt die intuitive Kombination von NPWT in einem patientenfreundlichen Design. Das 2024 eingeführte System ist zur Behandlung von chronischen Wunden konzipiert, die schätzungsweise 8,2 Millionen Menschen in den USA betreffen und eine jährliche finanzielle Belastung von 33 Milliarden US-Dollar verursachen.
Das RENASYS EDGE NPWT System ist leicht, kompakt und leise, sodass Patienten es problemlos tragen oder tragen können, ohne auf ihren Zustand aufmerksam zu machen. Diese Designüberlegung ist entscheidend, da 68 % der Patienten mit chronischen Wunden oft unsicher und isoliert werden. Smith+Nephews Fokus auf patientenorientiertes Design zeigt sich auch in ihrem PICO◊ 14 NPWT System, das 2021 ebenfalls einen Red Dot Award für Designkonzept für sein tragbares und diskretes Design gewonnen hat.
- None.
- None.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category, recognizing its intuitive pairing of NPWT housed in a patient-friendly design.
The Red Dot Awards celebrate new innovations and groundbreaking designs, with recipients ranging from concepts and prototypes to full Ready For Market products.
Launched in 2024, the RENASYS EDGE NPWT System is a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities.1
It is estimated that the annual financial burden of chronic wounds in the US is
Smith+Nephew’s PICO◊ 14 NPWT System also won a Red Dot Award for Design Concept in 2021 for its lightweight, discreet and portable design which provides patients with high mobility.5-7
-ends-
Enquiries
Media
| Dave Snyder | +1 978-749-1440 |
| Smith+Nephew | dave.snyder@smith-nephew.com |
* based on Medicare beneficiaries
References
- Smith+Nephew 2022. Internal Report. EO.AWM.PCS270.003.v1.
- Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014 Mar;37(3):651-8. Numbers are rounded where appropriate.
- Sen CK. Human wounds and its burden: An updated compendium of estimates. Advances in Wound Care, 2019; 8(2):39-48
- Phillips T, StantonB, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31(1):49–53
- Gilchrist B, et al. Paper presented at: SAWC; 2020; Virtual.
- Smith+Nephew 2020. Internal Report. 2001002.
- Smith+Nephew 2018. Internal Report. DS.18.066.R.
For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
FAQ
What award did Smith+Nephew's RENASYS EDGE NPWT System win in 2024?
What are the key features of the RENASYS EDGE NPWT System (SNN)?
How many people are affected by chronic wounds in the US according to the press release?
What is the annual financial burden of chronic wounds in the US?
Has Smith+Nephew (SNN) won any other Red Dot Awards for their wound therapy systems?
